Hormone replacement therapy and atherosclerosis in postmenopausal women: Does aging limit therapeutic benefits?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 8, 2007, Pages 1669-1672

  Barton, Matthias ^a   Meyer, Matthias R ^a   Haas, Elvira ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRONE; 2 METHOXYESTRONE; 3BETA HYDROXY 5(10),7 ESTRADIEN 17 ONE 3 SULFATE; 3BETA HYDROXY 5ALPHA PREGNAN 20 ONE; 5,7,9(10) ESTRATRIENE 3BETA,17BETA DIOL; 5ALPHA ANDROSTANE 3BETA OL 16 ONE; 5ALPHA ANDROSTANE 3BETA,16ALPHA DIOL; 5ALPHA ANDROSTANE 3BETA,17ALPHA DIOL; 5ALPHA PREG 16 EN 3BETA OL 20 ONE; 5ALPHA PREGNANE 3BETA,16ALPHA,20BETA TRIOL; 5ALPHA PREGNANE 3BETA,20BETA DIOL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN DERIVATIVE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE DERIVATIVE; SODIUM 17ALPHA DIHYDROEQUILENINSULFATE; SODIUM 17ALPHA DIHYDROEQUILINSULFATE; SODIUM 17ALPHA ESTRADIOLSULFATE; SODIUM 17BETA DIHYDROEQUILINSULFATE; SODIUM 17BETA ESTRADIOLSULFATE; SODIUM 17BETA HYDROEQUILENINSULFATE; SODIUM 4 PREGEN 20 OL 3 ONE SULFATE; SODIUM DELTA 8,9 DEHYDROESTRONSULFATE; SODIUM EQUILENINSULFATE; SODIUM EQUILINSULFATE; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; NORETHISTERONE;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; EDITORIAL; HEART INFARCTION; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; AGE; AGED; AGING; CORONARY ARTERY ATHEROSCLEROSIS; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; INCIDENCE; METHODOLOGY; MIDDLE AGED; NOTE; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGING; ATHEROSCLEROSIS; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 34547628345     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.106.130260     Document Type: Editorial

References (44)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
2. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006;47:1019-1026.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc. 1998;280:605-613.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc. 2002;288:321-333.
5. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66:295-306.
6. Bittner V. Menopause and cardiovascular risk cause or consequence? J Am Coll Cardiol. 2006;47:1984-1986.
7. Kok HS, van Asselt KM, van der Schouw YT, van der Tweel I, Peeters PH, Wilson PW, Pearson PL, Grobbee DE. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol. 2006;47:1976-1983.
8. Pick R, Stamler J, Rodbard S, Katz LN. The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation. 1952;6:276-280.
9. Marmorston J, Magdison O, Kuzma O, Moore FJ. Estrogen therapy in men with myocardial infarction. Side-effects with increasing dosage and time. J Am Med Assoc. 1960;174:241-244.
10. Marmorston J, Moore FJ, Hopkins CE, Kuzma OT, Weiner J. Clinical studies of long-term estrogen therapy in men with myocardial infarction. Proc Soc Exp Biol Med. 1962;110:400-408.
11. Stamler J, Pick R, Katz LN, Pick A, Kaplan BM, Berkson DM, Century D. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. J Am Med Assoc. 1963;183:632-638.
12. Mügge A, Riedel M, Barton M, Kuhn M, Lichtlen PR. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res. 1993;27:1939-1942.
13. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E- deficient mice. Proc Natl Acad Sci U S A. 1996;93:10022-10027.
14. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest. 2001;107:333-340.
15. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
16. Pepine CJ, Nichols WW. Estrogen and different aspects of vascular disease in women and men. Circ Res. 2006;99:459-461.
17. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A. 2006;103:13162-13167.
18. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146:624-632.
19. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630.
20. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y. Modulation of endotheliumdependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 1995;92:3431-3435.
21. English JL, Jacobs LO, Green G, Andrews TC. Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol. 1998;82:256-258.
22. Sorensen KE, Kristensen IB, Celermajer DS. Atherosclerosis in the human brachial artery. J Am Coll Cardiol. 1997;29:318-322.
23. Barton M, Cremer J, Mugge A. 17Beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol. 1998;362:73-76.
24. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dosedependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 1994;90:1964-1968.
25. Barton M, Dubey RK. Postmenopausal hormone-replacement therapy. N Engl J Med. 2002;346:63-65.
26. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril. 2005;84:1589-1601.
27. Mandavilli A. Hormone in the hot seat. Nat Med. 2006;12:8-9.
28. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
29. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-545.
30. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357-365.
31. Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006;9:108-118.
32. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693.
33. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabumni RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL. Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol. 2004;24:394-396.
34. Gohlke-Barwolf C, Regitz-Zagrosek V, Mueck AO, Strasser RH. [The value of hormone replacement therapy for prevention of coronary heart disease in women]. Z Kardiol. 2002;91:430-435.
35. Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM, Klein SM. Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest. 2006;24:126-131.
36. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer. 2006;16 Suppl 1:452-457.
37. Barton M. Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection. Expert Opin Investig Drugs. 2001;10:789-809.
38. Internet: http://www.clinicaltrials.gov/show/NCT00154180 (accessed September 11, 2006).
39. Internet: http://www.clinicaltrials.gov/show/NCT00114517 (accessed September 11, 2006).
40. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol. 2006;47:1741-1753.
41. Women's Health Initiative: not over yet. The largest study of women's health has raised at least as many questions as it has answered. Stay tuned. Harv Womens Health Watch. 2006;13:1-4.
42. Gierach GL, Johnson BD, Bairey Merz CN, Kelsey SF, Bittner V, Olson MB, Shaw LJ, Mankad S, Pepine CJ, Reis SE, Rogers WJ, Sharaf BL, Sopko G. Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol. 2006;47:S50-58.
43. Barton M. Aging and biomedicine 2005: where should we go from here? Cardiovasc Res. 2005;66:187-189.
44. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-1587.